Stock Analiz

Immuron Ltd IMRN

Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026

$0.88Market cap $7M
Open the interactive analysis →

Immuron Ltd (IMRN) is a healthcare company listed in the US with a market value of about $7M. In fiscal year 2025 it had revenue of $5M and net income of -$3M, a net margin of -71.6%.

Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 22% a year, a 5-year average ROIC of -28%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 33% below the current price.

About Immuron

Immuron is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. Revenue went from $744461 in 2016 to $5M in 2025, growth of about 22.9% a year. It was profitable in 0 of the last 10 years in our data.

Score: 2.0 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health4/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.5
P/B1.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−33%

Growth and quality

Revenue growth (1 yr)45.8%
Revenue growth (5 yrs, per year)22.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1309.5%
ROIC (5-yr avg.)-27.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$5M$3M$1M$526412$109277$2M$2M$1M$1M$744461
Net income-$3M-$5M-$3M-$2M-$6M-$2M-$3M-$2M-$5M-$5M
Free cash flow—-$4M-$2M-$2M-$3M-$2M-$1M-$3M-$5M-$4M
EPS (diluted)$-0.42$-0.57$-0.31$-0.24$-0.78$-0.25$-0.40$-0.28$-0.65$-0.65
Net margin-71.6%-141.5%-209.8%-373.0%-5751.6%-116.2%-195.0%-166.5%-487.3%-706.1%
ROIC-52.3%-36.1%-14.4%-9.8%-25.6%-40.7%-50.0%-28.5%-79.1%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Immuron stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 33% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Immuron pay a dividend?

Not currently.

Is Immuron a good stock to buy?

We do not give buy or sell advice. Immuron scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.